Interview with Peter Martin, COO, Norgine
Before joining Norgine in May 2004, you were active in larger pharmaceutical companies. What made you decide to join a smaller player? There were a few reasons. The first factor…
Address: Norgine
Norgine House
Widewater Place
Moorhall Road
Harefield
Uxbridge
UB9 6NS UK
Tel: +44 (0) 1895 826 600
Norgine is a specialty pharmaceutical company with an extensive and balanced pan-European presence. Above and beyond Europe, its products are sold in a total of 53 countries worldwide. Its areas of expertise are principally in gastroenterology, hepatology and incontinence.
Founded in 1906 by Dr Victor Stein, Norgine is still privately owned and Peter Stein, a grand-nephew of the founder, is now Chairman and CEO. The company’s core focus is on gastroenterology and hepatology. Norgine develops and manufactures innovative pharmaceutical products, which are then marketed through their own subsidiaries and in collaboration with a network of partners around the world.
Norgine’s total revenue in 2009 was €257 million. In 2009 product sales increased to €253 million, the 23rd consecutive year of double-digit growth at constant exchange rates. MOVICOL is Norgine’s number one product and accounts for over 50% of total sales.
Norgine currently has a strong product development pipeline including a number of projects entering advanced clinical studies.
The company has a manufacturing facility in the UK, but no R&D.
Movicol
Moviprep
Klean-Prep
Oramorph
Normacol
Pyralvex
Spasmonal
Fivasa
Nortussine
Xifaxan
Before joining Norgine in May 2004, you were active in larger pharmaceutical companies. What made you decide to join a smaller player? There were a few reasons. The first factor…
Airfinity’s Dr Patricia Gallego highlights the persistent threat that COVID-19 continues to present to patients and healthcare systems around the world and outlines the urgent need for more vaccine breakthroughs…
The UK government has decided to go ahead with a much-debated increase in the revenue clawback rate —from 24.4 percent to 27.5 percent— for drugmakers subject to its Statutory Scheme…
Dr Matt Linley, senior director for analytics and forecasting at predictive health analytics firm Airfinity, looks ahead to a potentially game-changing year in the fight against respiratory synctial virus (RSV),…
A roundup of the latest UK healthcare, pharma and biotech news including AbbVie and Lilly’s departure from the country’s voluntary medicines pricing agreement, Moderna’s expanded footprint, UK biotech’s 2022 funding…
What digital skills do pharma leaders need in order to drive transformation, deliver success at scale in the business, and prepare for next-gen customer engagement? Sarah Gilchriest explores the critical…
Bernard Ross, a serial entrepreneur with more than 20 years’ senior experience at private and public board level across multiple industries, looks ahead to 2023 and highlights five key trends…
After an almost 20-year career in Big Pharma culminating in a role as president of AstraZeneca UK, Lisa Anson took the leap into the biotech world to lead what at…
Pricing and market access have become increasingly hot topics in recent years, as healthcare systems across the world attempt to balance their own financial sustainability with securing the latest medical…
National Health Service (NHS) England CEO Amanda Pritchard has raised concerns about the state of British healthcare in recent weeks and months, proclaiming that the NHS is in a worse…
With the brief tenure of Liz Truss as Prime Minister already drawing to a close, the UK faces yet another new leader as the country attempts to extricate itself from…
“Life sciences are at the heart of my vision to build a country fit for the future,” tweeted new UK Prime Minister Liz Truss last month. Now installed as leader…
US biotech Moderna – producer of a messenger RNA (mRNA) COVID-19 vaccine that has found its way into 75 million arms in the US alone and generated USD 12 billion…
See our Cookie Privacy Policy Here
